Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial
First-In-Class Potential In Disease
The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.
